Researchers developed tumor-targeted nanoparticles designed to co-deliver a macrophage engager mRNA alongside PD-L1 antibodies to boost glioblastoma immunotherapy efficacy. The work, published in Nature Communications, describes a delivery system intended to concentrate immune-modulating therapy at tumor sites. The strategy combines immune activation through macrophage engagement with checkpoint inhibition via PD-L1 targeting, aiming to improve the strength and persistence of anti-tumor immune responses in a tumor type where immunotherapy has historically underperformed. The article emphasizes the preclinical promise of the formulation and delivery concept, which could support future translational studies focused on dosing, tolerability, and the durability of immune effects in vivo.